بعض محتويات هذا التطبيق غير متوفرة في الوقت الحالي.
إذا استمرت هذه الحالة ، يرجى الاتصال بنا علىتعليق وإتصال
1. (WO2018224548) POINT-OF-CARE TESTING OF PRO-THYMOSIN 100-109 FOR DETECTING SEPSIS
ملاحظة: نص مبني على عمليات التَعرف الضوئي على الحروف. الرجاء إستخدام صيغ PDF لقيمتها القانونية

CLAIMS

An in vitro method for determining the type and severity of a life-threatening condition of a patient due to bacterial infection, comprising the steps of:

a) performing an assay method for detecting the presence of a decapeptide comprising C-terminal amino acids 100 to 109 of human prothymosin a in a body sample obtained from said patient;

b) measuring the concentration of said decapeptide comprising amino acids 100 to 109 of human prothymosin a in the body sample;

c) comparing said measured concentration of said decapeptide comprising amino acids 100 to 109 of human prothymosin a to a predetermined reference upper value predictive of patient survival; and

d) assessing of said patient of suffering a life-threatening condition by assigning an increased likelihood of an adverse outcome when said measured concentration of said decapeptide comprising amino acids 100 to 109 of human prothymosin a is higher than said predetermined value early post-infection, or by assigning a decreased likelihood of an adverse outcome when said measured concentration of said decapeptide comprising amino acids 100 to 109 of human prothymosin a is lower than said predetermined value early post-infection.

The method of claim 1 , wherein said C-terminal amino acids 100 to 109 of human prothymosin a have amino acid sequence

SEQ ID NO: 1 TKKQKTDEDD.

The method of any claim 1 or 2, wherein said adverse outcome is sepsis or sepsis-related mortality.

The method of any claim 1 or 3, wherein said predetermined reference upper value predictive of patient survival is in the range from 4 to 6 ng/mL.

The method of any claim 1 to 4, wherein high levels of measured decapeptide comprising aminoacids 100 to 109 of human prothymosin a in said body sample early post- infection are indicative of augmented degree of cell necrosis and increased likelihood of sepsis-related mortality.

The method of any claim 1 to 5, wherein low levels of measured decapeptide comprising amino acids 100 to 109 of human prothymosin a in said body sample early post-infection are indicative of augmented degree of cell apoptosis and reduced likelihood of sepsis-related mortality.

The method of any claim 1 to 6, wherein said sample is selected from blood, serum or plasma sample.

The method of any claim 1 to 7, wherein a plurality of samples is obtained in a time-dependent manner.

The method of any claim 1 to 8, further comprising the step of determining the level of caspase-3 activation in said body sample.

The method of any claim 1 to 9, wherein said assay method for detecting the presence of said decapeptide comprising C-terminal amino acids 100 to 109 of human prothymosin a in a body sample is an immunoassay.

The method of any claim 1 to 10, wherein said immunoassay comprises contacting said body sample with a solid phase having at least one antibody that specifically binds a decapeptide comprising C-terminal amino acids 100 to 109 of human prothymosin a; and detecting the binding of said antibody.

Kit for determining a life-threatening condition of a patient due to bacterial infection, comprising

a) a solid phase having antibodies capable of binding a decapeptide comprising C-terminal amino acids 100 to 109 of human prothymosin a; and

b) reagents for the detection of said antibody-decapeptide complex, in a method according to claim 1.

The kit of claim 12, further comprising

a) blocking buffer containing 2 % w/v BSA;

b) washing buffer containing 150 mM NaCI, 10 mM phosphate buffer, 0.05 % Tween 20; and, optionally

c) coloring buffer containing 1 % 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid), 30% hydrogen peroxide.

* * * * *